poisar

Stocks · News reference

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug

Vandana Singh

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REGN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Prosper Junior Bakiny

    Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

    The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

    VRTXREGN
  3. Andy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    AMGNVRTXREGN